Navigation Links
NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
Date:11/12/2008

New Analysis of the 104 ABPM Study Presented at the American Heart

Association

http://www.nicox.com

SOPHIA ANTIPOLIS, France, November 12 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA. This ABPM pilot study in hypertensive volunteers was designed to compare the 24-hour blood pressure profiles of naproxcinod 750 mg bid and naproxen 500 mg bid. Naproxcinod is NicOx' lead investigational product and the first compound in the new Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents.

This new post hoc analysis was accepted by the American Heart Association scientific panel and compared the mean 24-hour systolic blood pressure (SBP) as measured by ABPM in the two groups (i.e. naproxcinod vs. naproxen), at the end of the 2 weeks of active treatment. The mean 24-hour SBP showed a difference of 2.4 mmHg (standard error 0.87 mmHg) in favor of naproxcinod as compared to naproxen (p=0.007) after 2 weeks of treatment. Interestingly, for the daytime measurements (the 8 hours following the morning dose), the mean 8-hour SBP showed a difference of 4.4 mmHg (standard error 0.98 mmHg) in favor of naproxcinod as compared to naproxen (p<0.0001) after 2 weeks of treatment.

"It was very interesting and rewarding to share these promising results with the medical community at the American Heart Association Scientific Sessions, which is one of the leading cardiology congresses worldwide," commented Jacques Djian MD, Cardiologist and Vice-President Translational Medicine at NicOx. "This new analysis of the blood pressure data from the 104 study follows the excellent top-line r
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

679

GOOD

Page: 1 2 3

Related biology technology :

1. NicOx Reports Results for the First Three Quarters of 2008
2. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
3. NicOx Announces Departure of Damian Marron for CEO Position
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
6. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
7. NicOx Opens U.S. Headquarters in New Jersey
8. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
9. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
10. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
11. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:9/30/2014)... 2014 Applying a well-known optical phenomenon called ... University has demonstrated the ability to "paint" ultra-thin ... holds promise for making future, flexible electronic devices, ... of next-gen rocket ships and spacecraft with extremely ... oil in water, it becomes iridescent, revealing a ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ... has received a Canadian Patent for Inhibition or ... patent includes claims using thymosin beta 4, various ... for these purposes.  The patent will expire in ... ( www.regenerx.com ) RegeneRx is ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... LOS ALAMOS, New Mexico, December 13, 2007In collaboration ... Alamos, an international team of researchers has, for ... formation of mysterious metallic puddles that facilitate the ... electrically conducting one. , The research may lead ...
... SAN DIEGO, Dec. 13 Neurocrine Biosciences,Inc. (Nasdaq: ... at its San Diego campus, as a part of ... and associated costs,and expenses after the setback on indiplon. ... "It is with great disappointment that we have to ...
... GRENOBLE France, December 13 ,STALLERGENES S.A and Protein,eXpert ... developing and pharmaceutically producing mites,recombinant allergens(1)., The ... programme for a recombinant protein treatment for sublingual,desensitisation ... up of the recombinant allergens Der p 1 ...
Cached Biology Technology:Collaboration yields 'the right glasses' for observing mystery behavior in electrons 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 3Neurocrine Announces Work Force Restructuring 2Neurocrine Announces Work Force Restructuring 3STALLERGENES and Protein' eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens 2STALLERGENES and Protein' eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens 3
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
(Date:9/29/2014)... the exposure to tar tended to be lower for ... Similarly, exposure to nicotine tended to be lower. , ... in several countries around the world. Previous studies have ... the smoke of these cigarettes are lower than those ... in the smoke are not necessarily linked to a ...
(Date:9/29/2014)... in school? According to a new Food and Brand ... meals can increase participation in the National School Lunch ... of vegetables by 16%! , Chefs Move to Schools ... pairs chefs with schools in order to provide nutrition ... food service workers. , A CMTS event was held ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Slim cigarette smokers not exposed to more harmful chemicals 2Chefs move to schools can increase school meal participation and vegetable intake among students 2
... , This release is available in German . ... chemically fix, stain or cut cells in order to study them. ... environment. The new method delivers an immediate 3-D image, thereby closing ... a high-resolution 3-D image of the entire cell in one step. ...
... Mass. Although people infected with HIV produce many antibodies ... are strangely ineffective at fighting the disease. A new study ... don,t work: they target the protein in a form it ... it,s too late, report researchers at Children,s Hospital Boston and ...
... Madrid, Friday November 19th, 2010. It is estimated ... / 10,000 people- affect about 6% of the European population. ... risk of having a newborn with a severe syndrome of ... affected by one of these diseases, being the most common ...
Cached Biology News:New microscope reveals ultrastructure of cells 2Designing more effective anti-HIV antibodies 2Designing more effective anti-HIV antibodies 3Spain is leading the fight against rare anemias in Europe 2